Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Daniel C Montano with Zhittya Genesis Medicine will be coming to Texas to take a look at Venturis’ financials so I have been informed.
Zhittya Genesis Medicine will seize Venturis assets I have been informed as part of the arbitration award.
Let me help you, CVBT Fan.
Zhittya did NOT win a lawsuit. The failed CEO of Shittya was awarded past wages in an arbitration, not a lawsuit. Unfortunately for FailedCEO, VT has a $2.5 million lawsuit award by the courts in Nevada. FailedCEO's wage award amounted to $800,000. So, bottom line, FailedCEO owes Venturis Therapeutics $1,700,000. Should we have a whip round to see if we can help FailedCEO. I reckon we could raise $10.49 for him. Only $1,699,989.51 to go...........................
History of a FAILED CEO
p.s. Shittya has no IP. VT has a comprehensive Patent Portfolio. Poor ol' FAILED CEO!!
Apart from anything else he hasn't won any cases. He was awarded his back pay of $800,000 in arbitration. Back pay earned when he was destroying VT. Remember his record. 2005 VT (then CVBT) was capitalized at $1.8 billion. In 2012 it was delisted due to Dan Montano's ineptitude at a value of $40 million.
But hey, Shittya has 2 billion followers on YouTube..........LOL.
Talking of YT I found this hilarious video of Dan's "expertise".
Daniel C. Montano, CEO Extraordinaire - LOL
VT 5 laps ahead in a 6 lap race.
"Zhittya Genesis Medicine is CardioVascular Biotherapeutics (Venturis Therapeutics) only competitor in the development of FGF-1. Zhittya Genesis Medicine was founded by the former CEO and founder of CVBT, Dan Montano. Zhittya Genesis Medicine has since soared (into oblivion) to the top since he left CVBT in 2014."
Zhittya isn't a competitor of VT. Zhittya is what is referred to in Las Vegas as, SMOKE & MIRRORS.
"Under the Marketplace Exclusivity, the first company to obtain approval gets an effective monopoly for 10 years. With Zhittya Genesis Medicine (ZGM) indubitably ahead of Venturis Therapeutics by about six years, it is clear who will be the first to monopolize the FGF-1 industry."
Zhittya is stumbling around in a Phase 1 trial in Mexico. They have treated ZERO patients. VT have a Phase 2 CAD trial ongoing & a Phase 2b/3 pivotal trials. In other words VT is around 5 laps ahead in a 6 lap race.
"Zhittya Genesis Medicine and Venturis/CVBT are the only two companies in the race to commercialize FGF-1. Clearly Zhittya Genesis Medicine is far ahead of Venturis in the race as their announcements clearly state that they now have a large batch of FGF-1 at their disposal, have started numerous clinical trials such as in Parkinson's Disease and ALS, have had countless webinars whose social media campaign has touched tens of millions of people, with their subscriber list at tens of thousands."
Countless webinars mean diddly squat with the US FDA. To reiterate VT is around 5 laps ahead in a 6 lap race.
"CVBT/Venturis has now lost Myerson, CVBT has now lost yet another major court battle, Venturis has now lost the majority of their administration. What do we have? There are no experts running Venturis Therapeutics, those experts fled the company after they testified in court that CVBT was lying!"
Again, completely erroneous. Myerson was fired by VT years ago. Refer to the VT presentation where it lists the comprehensive nature of the CVBT team. Anyone who wants the presentation can contact Grant Gordon (my source) at ggordon@venturistherapeutics.com. Needless to say the naysayers have no up to date information on VT as VT has deliberately flown under the RADAR for years which is changing as I write this.
With Daniel C. Montano's $1 million dollar judgement against CVBT/Venturis Therapeutics (WHICH CVBT/VENTURIS HAS NO OFFSET) it is clear that Dan Montano will be coming after Cardiovascular Biotherapeutics.
VT has offset due to Calvin Wallen assigning his $2.5 million judgement against Dan Montano to VT. This means that Dan Montano now owes VT $1.7 million.
Every Cardiovascular Biotherapeutics/Venturis Therapeutics shareholder has to keep up with Zhittya Genesis Medicine because they are our only competition! Our competition is leaving us in the dust, without a doubt they are six years ahead of us!
To reiterate (yet again) VT is around 5 laps ahead in a 6 lap race.
Ultimately I must ask, Zhittya Genesis Medicine has proven that in 6 years a lot of progress can be made. Where is CVBT/Venturis Therapeutics progress? We have made no drug, we have had no shareholders meeting, we have done nothing but lose court battle after court battle in the last half decade. We are losing. When will our CVBT management respond?
VT has drug & are in pivotal trials with the US FDA. Zhittya is in a Phase 1 trial in Mexico, not under FDA auspices.
Every CVBT shareholder should care.
Every VT shareholder does care and are pleased to be on the equivalent of a super yacht as opposed to SS Titanic (Dan Montano/Zhittya).
The one area that Dan Montano is miles ahead of VT & VT management is the number of failed/bankrupted businesses he’s been involved in scuppering. Something in the order of 20 failed businesses over the past 30 years. In addition Dan Montano is in personal bankruptcy. A SERIAL FAILURE.
VT has a comprehensive IP portfolio. Zhittya have nada, not one patent to its name. The failed CEO, Dan Montano, actually believes that in biotechnology IP is worthless. That alone tells you all you need to know about the failed CEO.
Imagine a company so great it's ONLY measure of success is it's record in the courtroom. Most companies I've worked for pride themselves on avoiding litigation. But not Daniel C Montano. Dan seems to welcome it. Because, you know, wasting money on lawyers is a great allocation of resources.
CVBT/VT has lost EVERY lawsuit to Zhittya Genesis Medicine/Zhittya Regenerative Medicine and Daniel C. Montano
Since Dan Montano left the company in 2014 to start Zhittya, our management has consistently attempted to harm the new company. After seven years of lawsuits, all of them have been ruled in favor of Zhittya Genesis as well as their CEO, Dan Montano. The most recent ruling has resulted in a $1 million dollar judgement against CVBT/VT, confirmed by the US Federal Court. This confirmation gives Zhittya and Dan Montano the ability to do a debtors exam in May.
What assets can Dan Montano take in this debtors exam?
Zhittya Genesis Medicine Lawsuit Against CardioVascular BioTherapeutics- victory for Zhittya Genesis Medicine confirmed by the US Federal Court
CVBT/Venturis Therapeutics' claim of IP theft was dismissed in total. Zhittya Genesis Medicine/Zhittya Regenerative Medicine was confirmed to own all of its IP without question. CVBT/VT's management's attempt to harm their competitor has backfired. Dan Montano, CEO of Zhittya Genesis Medicine/Zhittya Regenerative Medicine now has a judgement against CVBT/VT for $1 million dollars confirmed by the United States Federal Courts.
Zhittya Genesis Medicine vindicated by recent court ruling. All the crap about stealing IP from CVBT was bull - CVBT lost 100% of their arguments!
Zhittya Regenerative Medicine scores big legal win. Court case dismissed will allow smooth sailing for Dan Montano and company.
Zhittya Genesis Medicine retains IP with lawsuit win? Will this affect Venturis’ patents?
Zhittya Genesis Medicine wins lawsuit. As reported on this message board- what does that mean for Venturis?
Daniel C Montano speaks in Dubai at Family Offices Summit. Should Venturis be at meetings like these?
Zhittya Genesis Medicine set to treat Parkinson's disease patients in Mexico. They have been given approval to start! Where is Venturis on this?
Daniel C Montano announces that Zhittya Genesis Medicine will develop its own proprietary cardiac catheter to advance their heart trials. What catheter will Venturis be using?
Zhittya Genesis Medicine reports on potential new application to use FGF to treat lupus? Is this something Venturis science guys should look at?
When will CVBT ever do Clinical Trials?
Despite our new administration having the opportunity to restart clinical trials for the last six years, we have yet to make any progress whatsoever. Dan Montano's Zhittya Genesis Medicine has started new clinical trials in Parkinson's Disease and ALS with their new manufactured FGF-1. Cardiovascular BioTherapeutics/Venturis Therapeutics has not made new FGF-1 in over half-of-a-decade and has seen no progress whatsoever since Dan Montano left the company in 2014.
When will we start doing clinical trials? What have we been doing in the past six years to prepare for the restarting of our clinical trials? Do we even have new FGF-1 for those clinical trials???
CVBT/Venturis Therapeutics Misconduct results in Dan Montano's $1 million dollar judgement against CVBT/VT
Daniel Montano, founder of CVBT in 1998, left the company in 2014 to found Zhittya Genesis Medicine. CVBT/VT has since filed countless lawsuits, only to lose EVERY SINGLE LAWSUIT to Daniel C. Montano and Zhittya Genesis Medicine. The most recent lawsuit CVBT/Venturis Therapeutics filed against Zhittya Genesis Medicine and Daniel C. Montano has resulted in Zhittya Genesis Medicine being dismissed from the lawsuit, and Daniel Montano having a $1 million dollar judgement against CVBT/VT for their misconduct.
What will this million dollar judgement mean for the future of CVBT/VT? With an upcoming debtors exam for CVBT/VT how can we still raise money?
Zhittya Genesis Medicine dismissed from CVBT's Lawsuit
Cardiovascular Biohtherapeutics' lawsuit claiming that Zhittya Genesis Medicine stole Intellectual Property (IP) from CVBT/Venturis Therapeutics has been dismissed by the Nevada State Court, forcing CVBT/VT to acknowledge that Zhittya Genesis Medicine owns all of the IP it is now developing.
What does the ruling mean for CVBT?
Daniel C Montano with his newly won judgement will probably be heading to Texas to seize some of those tasty Venturis' assets! Yum, Yum.
Zhittya Genesis Medicine reports they are looking at intranasal delivery of FGF - We Venturis should check that out.
Daniel C Montano states that the pre-IPO for the Latin America marketing company will be closing soon - why is Venturis not raising money this way? Why is no one answering these questions?
Daniel C Montano and Zhittya Genesis Medicine are, in my opinion, real and serious competition for us at Venturis. Whoever gets FGF to market first will have a monopoly I am told. We better get moving!!
Zhittya Genesis Medicine has great webinars on their webpage. Where are Venturis' webinars?
Zhittya Genesis Medicine reports FGF-1 may be a potential treatment for autism. Has Venturis looked into this? This is an awful disease for kids.
No, a reduction in Montano's liability to Venturis. Montano was able to show he did not owe 2.7 M only 1.7 M. Thats all
CVBT Progress Update 2021?
Unfortunately, until recently this board has not been active on informing the shareholders of any news that CVBT/Venturis Therapeutics has in 2021. Since our administration feels that they cannot publicly share updates and news I have compiled a list of some things that I have found about CVBT/Venturis Therapeutics from 2021. If you have anymore please feel free to add:
*Lost another major court battle to Dan Montano resulting in Dan Montano's $1 million dollar judgement against CVBT, confirmed by the United States Federal Court
*Zhittya Genesis Medicine, among other defendants, were dismissed from CVBT's/Venturis Therapeutics' lawsuit.
*Yet another shareholders meeting has been scheduled, but as with the last ones will be postponed for another year.
*Our administration has yet to take any action to start drug production or revitalize the clinical trials.
*CVBT/Venturis Therapeutics has fallen even further behind Zhittya Genesis Medicine, as Zhittya Genesis Medicine now has FGF-1 completed and ready to go for their new and active clinical trials in Parkinson's Disease and ALS.
Other than those listed, has there been any other important news or updates regarding CVBT?
Where will CVBT get their catheters???
Zhittya Genesis Medicine has announced that they are now developing their own catheters for their future clinical trials. Such an innovation would likely give Zhittya Genesis Medicine a cutting edge over CVBT/Venturis Therapeutics, which has yet to even produce the FGF-1 molecule, already putting CVBT behind Zhittya Genesis Medicine by about 1-2 years.
If CVBT/Venturis Therapeutics makes the molecule and restarts the clinical trials after nearly a decade of inactivity, will we have to buy our catheters from Zhittya Genesis Medicine? If we have to buy our catheters from them how will that affect CVBT's strategy in the future?
UPCOMING DEBTORS EXAM
With Dan Montano's $1 million dollar judgement, confirmed by the United States Federal Court, against CVBT/Venturis Therapeutics a debtors exam is likely to happen. Since this claim appears unable to be offset by Venturis Therapeutics/CardioVascular BioTherapeutics (CVBT) how would a debtors exam affect the future of the company?
Would the debtors exam result bring forth the true financials of CVBT/Venturis Therapeutics? If it were to bring forth the true financials of our company, would that result in the deterioration if not shutting down of CVBT/Venturis Therapeutics?
Will our shareholders meeting address this pressing issue or will it be postponed again?
Dan Montano's Clear Victory over CVBT
CardioVascular BioTherapeutics/Venturis Therapeutics has lost yet another court battle to Dan Montano. As a result of this miserable defeat, the US Federal Court has confirmed Dan Montano's $1 million dollar judgment against CVBT/Venturis Therapeutics despite bringing on the case themselves!
Despite what individuals say on this page, there is no right of offset to this matter! Dan Montano's $1 million dollar judgement has no offset. The Court Records clearly indicate the Dan Montano's $1 million dollar judgement. Those same Court Records DO NOT INDICATE THAT VENTURIS THERAPEUTICS IS OWED ANYTHING FROM DAN MONTANO. There is no right of offset. We can only hope that Dan Montano will not initiate a debtor's exam.
Grant Gordon and Others have been WRONG for SEVEN YEARS
Many individuals from the CVBT/Venturis Therapeutics administration, including Grant Gordon amongst others, have consistently prophesied the impending downfall of Zhittya Genesis Medicine. If this were the case then:
Why has CVBT/Venturis Therapeutics lost every court battle to Dan Montano and Zhittya Genesis Medicine?
Why does Dan Montano have a judgement against CVBT/Venturis for $1 million dollars?
Why did Myerson, and other CVBT/VT experts, openly admit that our administration was lying when they brought fourth a suit to Zhittya Genesis Medicine and Dan Montano?
Why has the last seven years of professing of downfall only seen Zhittya Genesis Medicine and Dan Montano get stronger?
Why has Zhittya Genesis Medicine moved to creating FGF-1 and starting clinical trials while CVBT has yet to create FGF-1 and has not seen clinical trial activity in almost a decade?
DAN MONTANO STARTED THE CLINICAL TRIALS FOR CVBT
The members of this board are quick to argue that the former leadership has failed completely. On the contrary, the same clinical trails that our leadership touts as successes were started by Dan Montano, and have yet to move since Dan Montano left the company in 2014. The CVBT/Venturis Therapeutics leadership has been advertising their success from the past successes of Dan Montano, who now is successfully running Zhittya Genesis Medicine which has now created new FGF-1 and is starting clinical trials.
I cannot point to a single thing our leadership has done in the past 7 years that are on par with Phase II clinical trials which Venturis Therapeutics inherited from Dan Montano's efforts. What have we done in the last seven years other than IP?
VT Shareholder meeting in late June 2021.
JBDC, I heard the same thing that the meeting is tabled for June. I am really looking forward to it. As I understand it there is going to be some "very interesting" news coming out in the next few weeks.
Can't wait!
Great post, JBDC. As JBDC mentions, anyone who wishes to obtain relevant, up to date information on VT should contact Grant Gordon (the founder of VT). Like me, if you sign a confidentiality agreement he will send you a copy of the presentation which is informative. It is very professional.
Zhittya have to do webinars & the Money Shows to try to shake loose cash from the senior citizens who attend these events. Zhittya has zero institutional investors as Dan Montano cannot pass muster with serious investors. His history of destroying every business he's been involved in is an anathema for serious investors. No institution would invest into a company with a deadbeat CEO such as Dan.
Zhittya Genesis Medicine giving webinars in Dubai. Any upcoming webinars for Venturis on their efforts?
Zhittya Genesis Medicine is CardioVascular Biotherapeutics (Venturis Therapeutics) only competitor in the development of FGF-1. Zhittya Genesis Medicine was founded by the former CEO and founder of CVBT, Dan Montano. Zhittya Genesis Medicine has since soared to the top since he left CVBT in 2014.
Under the Marketplace Exclusivity, the first company to obtain approval gets an effective monopoly for 10 years. With Zhittya Genesis Medicine (ZGM) indubitably ahead of Venturis Therapeutics by about six years, it is clear who will be the first to monopolize the FGF-1 industry.
Zhittya Genesis Medicine and Venturis/CVBT are the only two companies in the race to commercialize FGF-1. Clearly Zhittya Genesis Medicine is far ahead of Venturis in the race as their announcements clearly state that they now have a large batch of FGF-1 at their disposal, have started numerous clinical trials such as in Parkinson's Disease and ALS, have had countless webinars whose social media campaign has touched tens of millions of people, with their subscriber list at tens of thousands.
CVBT/Venturis has now lost Myerson, CVBT has now lost yet another major court battle, Venturis has now lost the majority of their administration. What do we have? There are no experts running Venturis Therapeutics, those experts fled the company after they testified in court that CVBT was lying!
With Daniel C. Montano's $1 million dollar judgement against CVBT/Venturis Therapeutics (WHICH CVBT/VENTURIS HAS NO OFFSET) it is clear that Dan Montano will be coming after Cardiovascular Biotherapeutics.
Every Cardiovascular Biotherapeutics/Venturis Therapeutics shareholder has to keep up with Zhittya Genesis Medicine because they are our only competition! Our competition is leaving us in the dust, without a doubt they are six years ahead of us!
Ultimately I must ask, Zhittya Genesis Medicine has proven that in 6 years a lot of progress can be made. Where is CVBT/Venturis Therapeutics progress? We have made no drug, we have had no shareholders meeting, we have done nothing but lose court battle after court battle in the last half decade. We are losing. When will our CVBT management respond?
Every CVBT shareholder should care.
Why so many posts on Zhittya Genesis Medicine and not Venturis?
Zhittya Genesis Medicine announced that it has been approved to start a clinincal trial in ALS patients in Mexico. Is Venturis pursuing this medical indication? Why is no one from CVBT answering this?
DAN MONTANO OWES VT $1.7 MILLION
How can a bankrupt such as Dan possibly pay off this amount of award. VT must be happy as will the majority of VT shareholders.
Interesting. Please post the case details. I searched on PACER and there is no mention of any case brought by CVBT. Also, I'm interested in how you could you possibly know of any details on what CVBT people said??
Very strange!!
Zhittya Genesis Medicine announced they will starting a Parkinson's disease clinical trial in a few months. What is the status of Venturis (CVBT) study?
Seems to me Montano now only owes Venturis 1.7 million in which they will never receive. The tit for tat 1 million will wash and Venturis will keep plodding on. Nothing more needs to be said.
Zhittya Genesis Medicine DISMISSED from CVBT Lawsuit
In a lawsuit Cardiovascular Biotherapeutics filed against Zhittya Genesis Medicine, the Nevada State Court has dismissed Zhittya Genesis Medicine from the lawsuit. The lawsuit had that claimed that Zhittya Genesis Medicine was stealing trade secrets from CVBT which has since been thrown out of court.
The case was easily dismissed after CVBT'S OWN EXPERTS TESTIFIED THAT ZHITTYA GENESIS MEDICINE STOLE NOTHING FROM CVBT.
In a clear victory for Zhittya Genesis Medicine and Dan Montano, whose $1 million dollar judgement against Venturis Therapeutics will likely result in the downfall of CVBT, investors, including myself are wondering if CVBT will make it through 2021.
By the way, Zhittya Genesis Medicine in their Update also reports the development of intranasal delivery of their products. Is this something we should Venturis should be looking into?
Zhittya Genesis Medicine's Update reports they are developing a new cardiac catheter. Are we???
FEDERAL COURT CONFIRMS DAN MONTANO’S $1 MILLION DOLLAR CLAIM AGAINST CVBT
Mr. Dan Montano’s court victory confirmed by the federal court gives Mr. Montano an incredible vantage. With the universality of the federal court system this makes the claim good throughout the entire nation. In all 50 states and all territories of the United States CVBT owes Dan Montano $1 million dollars and attorney fees. This means that this decision is not only good in state of Nevada (where our former headquarters were), but also in the state of Texas!
I am genuinely concerned for the future of CVBT! With Dan Montano’s incredible vantage it is likely that CVBT won’t even make it through the debtors exam!
It was an award from a certain retired judge, Zimmerman. Nothing to do with Federal Courts.
My question is where the heck will Dan Montano get $1,700,000 to repay VT (the $2,500,000 award to Wallen, now VT, less the $800,000 awarded in back wages to DM)?
Also, as DM is still in bankruptcy will his creditors take action to get hold of the $800,000?
I've heard that the Shareholder Meeting has been slated for June 2021. As I understand it it'll be announced shortly together with some other very interesting and positive news. From my keyboard to GOD'S ears.
I believe this is a big deal for VT, particularly as it has the IP protection around it. In the most recent presentation from VT it has a statement from Chairman of the Board of Directors, Novo Nordisk as follows:-
Patents at the Core: the Biotech Business
World Intellectual Property Organisation - WIPO
“Anyone, I would imagine, who has tried
to create a biotech company knows just how important patents are. You learn this when you’re studying, and again at your first job, and if you haven’t done so before, you realize it the first time you
meet potential investors.”
Mads Øvlisen, Chairman of the Board of
Directors, Novo Nordisk
I would like to share the presentation with y'all but as I signed an NDA before they would send it to me, I need to check out whether I'd get into trouble for sending a link to it here.
I hope everyone has a great weekend.
Followers
|
39
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3647
|
Created
|
04/08/05
|
Type
|
Free
|
Moderators |
VENTURIS THERAPEUTICS (formerly Cardiovascular
Biotherapeutics or CVBT) is a dead, zombie company
that hasn't run a single clinical trial in nearly 15
years. Not even one patient (!) has been treated
since 2007. Venturis Therapeutics is insolvent,
illiquid, and is controlled and run by an individual
who was accused by the U.S government of
embezzling $14 million from his previous company.
Venturis' lawyer, Barry Cannaday of Dentons (one
of the largest law firms in the U.S.), withdrew from
representing Venturis in April 2021 because Dentons
is owed over $200,000 by Venturis, and Mr. Cannaday
attested that "there are currently no assets or
revenue streams" to pay Dentons. Yet anonymous
advocates for Venturis (who I personally believe are
the company's desperate leadership) lie about public
facts that are easily verifiable. One of the most
absurd false claims is that there are (allegedly) two
ongoing pivotal clinical trials (see that particular
false claim below). These "clinical trials" exist only
in cyberspace but not in the real world the rest of us
(including Dentons) live in. That said, enjoy the
entertainment that lies below. Hopefully it gives you
some good laughs - that's about all that's left from
this dead, zombie company. Enjoy!
VENTURIS THERAPEUTICS (VT) OVERVIEW
VT was almost bankrupted by the original
CEO, Daniel C. Montano, and was rescued by
Calvin Wallen, Grant Gordon and then CFO,
Mickael Flaa.
VT had almost $40,000,000 in debt & was
effectively insolvent. The board of directors
who replaced the Dan Montano cronies
rehabilitated VT so that today the company has
almost zero debt and an comprehensive patent
portfolio. Under the disasterous management
of Dan Montano, the company had zero
patents.
Our Approach in Science and Technology:
Venturis Therapeutics, Inc. is a clinical stage
biopharmaceutical company advancing novel
therapeutics to address diseases such as
diabetic wounds, severe ischemic heart disease
and
peripheral artery disease. Our pre-clinical
therapeutic programs include erectile
dysfunction,
infarct stroke, degenerative disk disease and
Parkinson’s Disease.
Venturis Therapeutics, Inc. is focused on
targeted delivery of next generation
molecules which will improve the quality of life
for those suffering from vascular dysfunction.
We employ human proteins from the Fibroblast
Growth Factor family. Our lead candidate
stimulates the growth of new blood vessels when
administered to ischemic organs and
tissues. These anatomical targets are shown in
our pipeline section of the website.
www.vt.care
VENTURIS THERAPEUTICS (VT) OVERVIEW
VT was almost bankrupted by the original
CEO, Daniel C. Montano, and was rescued by
Calvin Wallen, Grant Gordon and then CFO,
Mickael Flaa.
VT had almost $40,000,000 in debt & was
effectively insolvent. The board of directors
who replaced the Dan Montano cronies
rehabilitated VT so that today the company has
almost zero debt and an comprehensive patent
portfolio. Under the disasterous management
of Dan Montano, the company had zero
patents.
Our Approach in Science and Technology:
Venturis Therapeutics, Inc. is a clinical stage
biopharmaceutical company advancing novel
therapeutics to address diseases such as
diabetic wounds, severe ischemic heart disease
and
peripheral artery disease. Our pre-clinical
therapeutic programs include erectile
dysfunction,
infarct stroke, degenerative disk disease and
Parkinson’s Disease.
Venturis Therapeutics, Inc. is focused on
targeted delivery of next generation
molecules which will improve the quality of life
for those suffering from vascular dysfunction.
We employ human proteins from the Fibroblast
Growth Factor family. Our lead candidate
stimulates the growth of new blood vessels when
administered to ischemic organs and
tissues. These anatomical targets are shown in
our pipeline section of the website.
www.vt.care
VENTURIS THERAPEUTICS OVERVIEW
Our Approach in Science and Technology:
Venturis Therapeutics, Inc. is a clinical stage biopharmaceutical company advancing novel
therapeutics to address diseases such as diabetic wounds, severe ischemic heart disease and
peripheral artery disease. Our pre-clinical therapeutic programs include erectile dysfunction,
infarct stroke, degenerative disk disease and Parkinson’s Disease.
Venturis Therapeutics, Inc. is focused on targeted delivery of next generation
molecules which will improve the quality of life for those suffering from vascular dysfunction.
We employ human proteins from the Fibroblast Growth Factor family. Our lead candidate
stimulates the growth of new blood vessels when administered to ischemic organs and
tissues. These anatomical targets are shown in our pipeline section.
vt.care
Venturis Therapeutics (VT) is
a biotechnology company based
in Dallas, Texas. VT has pivotal trials
ongoing in Ischemic Heart Disease &
Diabetic Foot Ulcers.
VT has a comprehensive patent
portfolio protecting its therapeutic
programs.
Venturis Therapeutics (VT) is
a biotechnology company based
in Dallas, Texas. VT has pivotal trials
ongoing in Ischemic Heart Disease &
Diabetic Foot Ulcers.
VT has a comprehensive patent
portfolio protecting its therapeutic
programs.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |